Skip to Main Content
About this Publication
Extrapulmonary neoplasms in lung cancer screening.
Pubmed ID
30050774 (View this publication on the PubMed website)
Digital Object Identifier
Transl Lung Cancer Res. 2018 Jun; Volume 7 (Issue 3): Pages 368-375
Godoy MCB, White CS, Erasmus JJ, Wu CC, Truong MT, Munden RF, Chiles C
  • Department of Diagnostic Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Department of Radiology, University of Maryland Medical Center, Baltimore, MD, USA.
  • Department of Radiology, Wake Forest University Health Sciences Center, Winston-Salem, NC, USA.

A significant reduction in lung cancer specific mortality rate was demonstrated by the National Lung Screening Trial (NLST) in participants who had annual low-dose computed tomography (LDCT) screening. In addition to early detection of lung cancer, lung cancer screening (LCS) provides an opportunity to detect cardiovascular disease, pulmonary disease (such as chronic obstructive pulmonary disease and interstitial lung disease), and extrapulmonary neoplasms, such as thyroid, breast, kidney, liver, esophageal, pancreatic and mediastinal tumors. Considering the fact that 22.3% of the certified deaths in the computed tomography (CT) arm of the NLST trial were due to extrapulmonary malignancies, compared to 22.9% of deaths from lung cancer, it is possible that early diagnosis and treatment of clinically significant incidental findings may further decrease morbidity and mortality in screening participants. In this article we review prevalence, clinical relevance and management of incidentally detected extrapulmonary malignancies.

Related CDAS Studies
Related CDAS Projects